Hyperpolarized Xe129 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	1
299	Cystic fibrosis	1

85. Idiopathic interstitial pneumonia

---

Clinical trials : 598 /  Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04677426 (ClinicalTrials.gov)	January 1, 2022	16/12/2020	129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study	129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study	Idiopathic Pulmonary Fibrosis;Hypersensitivity Pneumonitis	Drug: Hyperpolarized Xe129	University of Kansas Medical Center	Duke University;Children's Hospital Medical Center, Cincinnati;Boehringer Ingelheim	Not yet recruiting	18 Years	N/A	All	40	Phase 2	NULL

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04624490 (ClinicalTrials.gov)	November 2, 2020	31/10/2020	Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease	Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease	Asthma;COPD;Interstitial Lung Disease;Cystic Fibrosis;Pulmonary Hypertension;Pulmonary Infection;Other Lung Disease	Drug: Hyperpolarized Xe129	Mario Castro, MD, MPH	NULL	Recruiting	3 Years	N/A	All	260	Phase 1	United States